[1] 郑荣寿, 孙可欣, 张思维. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. [2] Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al.Global, Regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2018, 4(11): 1553-1568. [3] 新华社. 中共中央、国务院印发<“健康中国2030”规划纲要>[EB/OL]. [2016-10-25]. http: / / www.gov.cn/ zhengce/2016-10/25/content_5124174. Htm [4] Jansana A. Posso M, Guerrero I.Health care services use among long-term breast cancer survivors: a systematic review[J]. J Cancer Surviv, 2019, 13(3): 477-493. [5] Doose M, Steinberg MB, Xing CY.Comorbidity Management in Black Women Diagnosed with Breast Cancer: the Role of Primary Care in Shared Care[J]. J Gen Intern Med, 2021, 36(1): 138-146. [6] 中国健康促进基金会乳腺癌防治专家委员会. 乳腺癌预防科普宣教专家共识(2018版)[J]. 中华健康管理学杂志, 2019, 13(3): 188-194. [7] Jasra S, Anampa J.Anthracycline use for early stage breast cancer in the modern era: a review[J]. Curr Treat Options Oncol, 2018, 19(6): 1-17. [8] Dempsey N, Rosenthal A, Dabas N, et al.Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies[J]. Breast Cancer Res Treat, 2021, 188(1): 21-36. [9] Gernaat SAM, Ho PJ, Rijnberg N, et al.Risk of death from cardiovascular disease following breast cancer: a systematic review[J]. Breast Cancer Res Treat, 2017, 164(3): 537-555. [10] Haque R, Prout M, Geiger AM, et al.Comorbidities and cardiovascular disease risk in older breast cancer survivors[J]. Am J Manag Care, 2014, 20(1): 86-92. |